[go: up one dir, main page]

ECSP12011994A - Formulación que comprende antagonistas del receptor ampa de 1h-quinazolin-2,4-diona, en la forma de tabletas de liberación inmediata y preparación de las mismasformulación que comprende antagonistas del receptor ampa de 1h-quinazolin-2,4-diona, en la fov - Google Patents

Formulación que comprende antagonistas del receptor ampa de 1h-quinazolin-2,4-diona, en la forma de tabletas de liberación inmediata y preparación de las mismasformulación que comprende antagonistas del receptor ampa de 1h-quinazolin-2,4-diona, en la fov

Info

Publication number
ECSP12011994A
ECSP12011994A ECSP12011994A ECSP12011994A EC SP12011994 A ECSP12011994 A EC SP12011994A EC SP12011994 A ECSP12011994 A EC SP12011994A EC SP12011994 A ECSP12011994 A EC SP12011994A
Authority
EC
Ecuador
Prior art keywords
includes antagonists
ampa
receiver
quinaziona
formformulation
Prior art date
Application number
Other languages
English (en)
Inventor
Joseph Lawrence Zielinski
John Vrettos
Qin Ji
Subash Patel
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43610748&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP12011994(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP12011994A publication Critical patent/ECSP12011994A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/10Ophthalmic agents for accommodation disorders, e.g. myopia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Addiction (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ECSP12011994 2009-12-22 2012-06-21 Formulación que comprende antagonistas del receptor ampa de 1h-quinazolin-2,4-diona, en la forma de tabletas de liberación inmediata y preparación de las mismasformulación que comprende antagonistas del receptor ampa de 1h-quinazolin-2,4-diona, en la fov ECSP12011994A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28898509P 2009-12-22 2009-12-22

Publications (1)

Publication Number Publication Date
ECSP12011994A true ECSP12011994A (es) 2012-07-31

Family

ID=43610748

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP12011994 ECSP12011994A (es) 2009-12-22 2012-06-21 Formulación que comprende antagonistas del receptor ampa de 1h-quinazolin-2,4-diona, en la forma de tabletas de liberación inmediata y preparación de las mismasformulación que comprende antagonistas del receptor ampa de 1h-quinazolin-2,4-diona, en la fov

Country Status (20)

Country Link
US (1) US20120263791A1 (es)
EP (1) EP2515873A1 (es)
JP (1) JP2013515076A (es)
KR (1) KR20120105035A (es)
CN (2) CN104013587A (es)
AU (1) AU2010336510B2 (es)
BR (1) BR112012016920A2 (es)
CA (1) CA2784996A1 (es)
CL (1) CL2012001689A1 (es)
EC (1) ECSP12011994A (es)
GT (1) GT201200209A (es)
MA (1) MA33834B1 (es)
MX (1) MX2012007320A (es)
NZ (1) NZ600717A (es)
PE (1) PE20121394A1 (es)
PH (1) PH12012501289A1 (es)
RU (1) RU2012131051A (es)
SG (1) SG181787A1 (es)
WO (1) WO2011079119A1 (es)
ZA (1) ZA201204607B (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2465693A1 (en) * 2003-06-12 2004-12-12 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
GB0416730D0 (en) * 2004-07-27 2004-09-01 Novartis Ag Organic compounds
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
WO2006110811A1 (en) * 2005-04-12 2006-10-19 Elan Pharma International Limited Nanoparticulate quinazoline derivative formulations
JOP20180109A1 (ar) * 2005-09-29 2019-01-30 Novartis Ag تركيبة جديدة
EP1968553A2 (en) * 2005-11-09 2008-09-17 Novartis AG Process for making pharmaceutical compositions with a transient plasticizer
US8673353B2 (en) * 2008-02-11 2014-03-18 Dainippon Sumitomo Pharma Co., Ltd Tablet having improved elution properties

Also Published As

Publication number Publication date
CA2784996A1 (en) 2011-06-30
EP2515873A1 (en) 2012-10-31
MX2012007320A (es) 2012-07-20
MA33834B1 (fr) 2012-12-03
BR112012016920A2 (pt) 2016-04-12
SG181787A1 (en) 2012-07-30
GT201200209A (es) 2013-09-09
AU2010336510B2 (en) 2014-06-26
WO2011079119A1 (en) 2011-06-30
RU2012131051A (ru) 2014-01-27
CN104013587A (zh) 2014-09-03
KR20120105035A (ko) 2012-09-24
PH12012501289A1 (en) 2013-01-07
PE20121394A1 (es) 2012-10-29
JP2013515076A (ja) 2013-05-02
AU2010336510A1 (en) 2012-07-12
CN102770124A (zh) 2012-11-07
NZ600717A (en) 2014-06-27
ZA201204607B (en) 2013-02-27
US20120263791A1 (en) 2012-10-18
CL2012001689A1 (es) 2013-01-11

Similar Documents

Publication Publication Date Title
FR25C1035I1 (fr) Formulations de comprimés de maléate de nératinib
SMT201500097B (it) Derivati di 4-amminopirimidina e loro uso come antagonsiti del recettore di adenosina a2a
BR112012011733A2 (pt) formulações de comprimido de liberação imediata
ATE518527T1 (de) Rasagilinformulierung mit verzögerter freisetzung
IL205947A0 (en) Phosphonic acid derivatives and their use as p2y12 receptor antagonists
BR112012008109A2 (pt) antagonistas de pirimidin- e triazin-hepcidina
EP2875360A4 (en) IN VITRO TEST FOR THE PREDICT OF RENALER PROXIMAL TUBULAR TOXICITY
BRPI0908596A2 (pt) formulação e composição farmacêutica de liberação prolongada
EP2395835A4 (en) S1P5 RECEPTOR AGONISTS AND ANTAGONISTS, AND METHODS OF USE
BRPI0911563A2 (pt) uso de antagonista da progesterona
BRPI0821732A2 (pt) Formulações de liberação controlada , forma de dosagem sólida, e, uso da formulação de liberação controlada
BR112015004397A2 (pt) formulações de anticorpos de receptor anti-prolactina.
EP2396070C0 (en) DRUG DELIVERY BY HYDROGELS CAPS
BR112012013148A2 (pt) formulação farmacêutica e uso
IT1398930B1 (it) Formulazioni farmaceutiche bistrato contenenti agonisti ed antagonisti oppioidi.
DK2821407T3 (da) Piperidinoncarboxamidazaindan-cgrp receptorantagonister
IL218490A (en) Oxazolopyrimidinones dihydro hydroxybencyalkyloxymethyl are converted, preparations containing them and their use in the preparation of pharmaceutical preparations
HUE055201T2 (hu) Triazolo[4,5-D]pirimidin-származékok mint CBB2-receptor-antagonisták
BRPI0912428A2 (pt) formulação farmacêutica sólida de liberação retardada
EP2576622A4 (en) ON THE UNPROCESSED RECEPTOR TYROSINE KINASE C-MET TARGETED ANTIBODIES
BR112013004662A2 (pt) agonistas de receptores de neurotrofina e o uso destes como medicamentos
BRPI0914225A2 (pt) preparação de formas galênicas de liberação controlada de relaxantes do músculo-esquelético
EP2254413A4 (en) IMIDAZOBENZAZEPIN-CGRP receptor antagonists
EP2599490A4 (en) COMPOSITION FOR TREATMENT OF INJURY, FORMULATION AND USE THEREOF
SMT201500293B (it) Antagonisti del recettore toll-like 3